Market Strategy - The market is experiencing fluctuations, with the Shanghai Composite Index slightly rising, achieving a fourteen-day consecutive increase [7] - The overall A-share market saw a 0.19% increase, closing at 6654.1 points, while the Shanghai Composite Index rose by 0.05% to 4085.77 points [7] - The hard technology sector is performing well, with the Sci-Tech 50 Index increasing by 0.99% [7] Industry Dynamics - In 2025, the number of new A-share accounts reached 27.44 million, a 10% increase compared to 2024 [27] - The market for on-site food production in supermarkets in China has surpassed 100 billion yuan, with major supermarket chains achieving a sales share of 10%-20% [29] - A subsidiary of China Communications Construction Company, along with CRRC and MTR, secured over 7 billion Australian dollars in contracts for the Sydney Metro project [31][33] Company Tracking - GF Securities plans to raise capital for its overseas subsidiary through a combination of private placement and convertible bonds, aiming to raise approximately 6.11 billion Hong Kong dollars [34] - Xianle Health obtained 9 invention patents and 2 health food registration certificates in Q4 2025, enhancing its product pipeline [36] - Qianjin Pharmaceutical received drug registration certificates for several products, which will contribute to the company's sustainable development [38]

Policy Developments - The National Medical Products Administration (NMPA) aims for a drug inspection pass rate of over 99% by 2025, with 19,700 batches to be inspected, ensuring overall drug safety stability in the country [1] Drug and Device Approvals - Qianjin Pharmaceutical announced that it and its subsidiary received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), enhancing its product pipeline for sustainable development [2] - Haizhi Pharmaceutical's subsidiary received acceptance for the listing application of HSK39297 tablets, intended for treating adults with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [3] - Xuantai Pharmaceutical obtained a drug registration certificate for injectable Isavuconazole, which is used to treat invasive aspergillosis and mucormycosis in adults [4] Capital Market Insights - Xiangyu Medical reported that as of the end of 2025, its brain-computer interface products have not achieved large-scale sales, with revenue contribution remaining minimal due to delays in bidding and sales processes [5] - Sanbo Brain Science clarified that it does not engage in the research, production, or sales of brain-computer interface products, and the revenue from neuro-regulation technology is negligible [6] - Weisi Medical stated that its new products in the brain-computer interface field are still in the early market cultivation stage, with limited revenue contribution [7] - Qiangna Technology, a "unicorn" in the brain-computer interface sector, completed approximately 2 billion RMB in financing, marking the second-largest financing in the field after Neuralink [8] - Baihua Pharmaceutical announced the termination of its control change plan due to a lack of consensus with the controlling shareholder, with stock resuming trading on January 7, 2026 [9] Industry Developments - Puluo Pharmaceutical signed a strategic cooperation framework agreement with Xi'an Xintong Pharmaceutical Research Co., Ltd. to collaborate on innovative drug research and outsourced production projects [10] - Yong'an Pharmaceutical plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd., with recent financial data showing total assets of 180 million RMB and a net profit of -1.12 million RMB for the subsidiary [11] - Baiyang Pharmaceutical established a collaborative innovation laboratory with Capital Medical University Xuanwu Hospital to focus on cutting-edge medical research in neuroscience and thoracic surgery [12] - Insilico Medicine announced an $888 million collaboration with Servier for the development of anti-tumor drugs, with potential upfront payments and milestone payments involved [13] Public Sentiment Alerts - WuXi AppTec disclosed that shareholders controlled by the actual controller have cumulatively reduced their holdings by 59.6751 million shares, accounting for 2% of the total share capital, with the reduction completed on January 5, 2026 [14]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) from the National Medical Products Administration, indicating successful consistency evaluation and enhancing the company's product pipeline, which is beneficial for sustainable development [1] Group 1 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have obtained drug registration certificates for three new products [1] - The approval of Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets signifies that these products have passed the consistency evaluation [1] - The addition of these products to the company's portfolio is expected to enrich its product pipeline and support sustainable growth [1]

Group 1 - The core point of the article is that Qianjin Pharmaceutical has received drug registration certificates for three products from the National Medical Products Administration, indicating a significant regulatory approval milestone for the company [1] Group 2 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical, received approval for Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets [1] - The approval of these drugs may enhance the company's product portfolio and market competitiveness in the pharmaceutical industry [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) and its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. have received drug registration certificates from the National Medical Products Administration for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] Group 1: Drug Approvals - The company has obtained approval for Dydrogesterone, a synthetic progestogen used for treating diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib is a Janus kinase (JAK) inhibitor that blocks the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation, developed in collaboration with Eli Lilly and Incyte [1] - Dapagliflozin is indicated for the treatment of type 2 diabetes [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) from the National Medical Products Administration, indicating successful consistency evaluation and enhancing the company's product pipeline, which is beneficial for sustainable development [1][1][1] Group 1 - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have obtained drug registration certificates for three new products [1] - The approval of Dydrogesterone tablets, Baricitinib tablets, and Dapagliflozin tablets signifies the company's successful compliance with consistency evaluation [1] - The addition of these products to the company's portfolio is expected to contribute positively to its sustainable growth [1]

Core Viewpoint - Qianjin Pharmaceutical (600479) has received approval from the National Medical Products Administration for the registration of three new drugs, indicating a significant advancement in its product portfolio and potential market opportunities [1] Group 1: Drug Approvals - Qianjin Pharmaceutical and its subsidiary, Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd., have received drug registration certificates for Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg) [1] - Dydrogesterone tablets are indicated for the treatment of diseases caused by endogenous progesterone deficiency and for luteal support in assisted reproductive technology [1] - Baricitinib tablets are a Janus kinase (JAK) inhibitor that can block the activity of one or more members of the JAK kinase family, thereby inhibiting pathways that activate inflammation [1] - Dapagliflozin tablets are used for the treatment of type 2 diabetes [1]

Core Viewpoint - Qianjin Pharmaceutical (600479.SH) has received approval from the National Medical Products Administration for the registration of Dydrogesterone tablets, Baricitinib tablets (4mg, 2mg), and Dapagliflozin tablets (5mg, 10mg), which will enhance the company's product pipeline and support sustainable development [1] Group 1 - The approval of these drugs will enrich the company's product offerings [1] - The new products are expected to contribute positively to the company's growth and sustainability [1] - There are uncertainties related to drug production and sales due to policy and market environment factors [1]

Core Viewpoint - Beijing Fuyuan Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Aisheng Pharmaceutical Co., Ltd., has received a drug registration certificate from the National Medical Products Administration for Dydrogesterone Tablets, which will enhance the company's product line and market competitiveness [1][4]. Drug Registration Certificate Details - The drug registration certificate for Dydrogesterone Tablets (10mg) was issued by the National Medical Products Administration, indicating that the drug has passed the consistency evaluation as per national policies [1]. Drug Information - Dydrogesterone is an orally absorbable synthetic progestogen, originally developed by Solvay Pharmaceuticals and approved for market in Portugal in July 1961. It was approved for sale in China in December 2002 for treating endogenous progesterone deficiency and supporting luteal function in assisted reproductive technology [1][2]. R&D Investment - As of the announcement date, Zhejiang Aisheng has invested a total of RMB 5.3716 million (approximately 0.537 million) in the research and development of this drug [2]. Market Status of Similar Drugs - According to data from Minai Network, the sales revenue of Dydrogesterone Tablets in China's three major terminal markets is approximately RMB 2.57 billion (approximately 25.70 million), with public hospitals accounting for RMB 2.20 billion (approximately 22.01 million), community health centers and township hospitals for RMB 61 million (approximately 0.61 million), and retail pharmacies and online pharmacies for RMB 308 million (approximately 3.08 million) [3].

Group 1 - The core point of the article is that Fuyuan Pharmaceutical announced the approval of its subsidiary Zhejiang Aisheng Pharmaceutical's drug, Dydrogesterone Tablets (10mg), by the National Medical Products Administration [2][3] Group 2 - The drug has received a production license, indicating a significant milestone for the company [2] - This approval may enhance the company's product portfolio and market presence in the pharmaceutical industry [2]